ArticleJournal for immunotherapy of cancer2025

Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.

Michiel M Smeenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.